Apomorphine infusion for improving sleep in Parkinson's disease

K Ray Chaudhuri¹, Valentina Leta²

Affiliations

¹ Department of Basic and Clinical Neurosciences, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 9RT, UK; Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK. Electronic address: ray.chaudhuri@kcl.ac.uk.
² Department of Basic and Clinical Neurosciences, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 9RT, UK; Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK.

PMID: 35429469
DOI: 10.1016/S1474-4422(22)00128-4

Comment

Apomorphine infusion for improving sleep in Parkinson's disease

K Ray Chaudhuri et al. Lancet Neurol. 2022 May.

. 2022 May;21(5):395-398.

doi: 10.1016/S1474-4422(22)00128-4.

Authors

K Ray Chaudhuri¹, Valentina Leta²

Affiliations

¹ Department of Basic and Clinical Neurosciences, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 9RT, UK; Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK. Electronic address: ray.chaudhuri@kcl.ac.uk.
² Department of Basic and Clinical Neurosciences, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 9RT, UK; Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK.

PMID: 35429469
DOI: 10.1016/S1474-4422(22)00128-4

No abstract available

PubMed Disclaimer

Conflict of interest statement

KRC declares grant support from Bial, Britannia, AbbVie, UCB, GKC, EU Horizon 2020, Parkinson's UK, NIHR, Parkinson's Foundation, Wellcome Trust, Kirby Laing Foundation, and MRC; has served as an advisory board member for, received consultancy and speaking fees from, and declares travel support from, AbbVie, UCB, GKC, Bial, Cynapsus, Lobsor, Stada, Zambon, Profile Pharma, Synovion, Roche, Theravance, Scion, Britannia, Acadia, 4D Pharma, and Medtronic; reports royalties or licenses from Oxford and Cambridge publishers (books) and the Mapi Institute (KPPS, PDSS 2); and has received payment for expert testimony from GMC. VL declares honoraria for speaking and manuscript writing from Britannia.

Comment on

Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study.
De Cock VC, Dodet P, Leu-Semenescu S, Aerts C, Castelnovo G, Abril B, Drapier S, Olivet H, Corbillé AG, Leclair-Visonneau L, Sallansonnet-Froment M, Lebouteux M, Anheim M, Ruppert E, Vitello N, Eusebio A, Lambert I, Marques A, Fantini ML, Devos D, Monaca C, Benard-Serre N, Lacombe S, Vidailhet M, Arnulf I, Doulazmi M, Roze E. De Cock VC, et al. Lancet Neurol. 2022 May;21(5):428-437. doi: 10.1016/S1474-4422(22)00085-0. Lancet Neurol. 2022. PMID: 35429481 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Apomorphine infusion for improving sleep in Parkinson's disease

Affiliations

Apomorphine infusion for improving sleep in Parkinson's disease

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical